120 Participants Needed

Ketamine for Methamphetamine Use Disorder

(KMD Trial)

Recruiting at 2 trial locations
MD
MJ
AS
AC
AL
Overseen ByAlain Litwin, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: University of Texas Southwestern Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team during the screening visit.

What data supports the effectiveness of the drug Ketamine Hydrochloride for Methamphetamine Use Disorder?

Research shows that ketamine can have rapid antidepressant effects in people with mood disorders, and it is effective for sedation and pain relief in medical procedures. This suggests it might help with methamphetamine use disorder by addressing mood issues and providing sedation.12345

Is ketamine safe for use in humans?

Research shows that ketamine, often used with midazolam, is generally safe for sedation in both children and adults, with some side effects like nausea and vomiting. It has been used safely in emergency and pain management settings, especially in children, with no major complications reported.678910

How is the drug combination of ketamine and midazolam unique for treating methamphetamine use disorder?

The combination of ketamine and midazolam is unique because ketamine can provide deep sedation and has been used effectively for procedural sedation, while midazolam helps reduce anxiety and unpleasant side effects associated with ketamine. This combination may offer a novel approach for methamphetamine use disorder, as there are no standard treatments specifically for this condition.24101112

Research Team

MJ

Manish Jha, MBBS

Principal Investigator

Associate Professor

Eligibility Criteria

Adults with moderate to severe methamphetamine use disorder (MUD) can join this study. The trial is designed for those who are seeking treatment and have not found success with other options.

Inclusion Criteria

I am between 18 and 65 years old.
Use acceptable methods of contraception during participation in the study
Be interested in reducing or stopping methamphetamine use
See 2 more

Exclusion Criteria

Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent
Be currently in jail, prison, or inpatient overnight facility as required by court of law
I have surgery scheduled soon.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either IV ketamine or IV midazolam over six weeks, with eight infusions and weekly medical management sessions

6 weeks
8 visits (in-person) for infusions, 6 visits (in-person) for medical management

Cognitive Behavioral Therapy

Participants engage in weekly cognitive behavioral therapy sessions on non-infusion days

12 weeks
12 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Ketamine Hydrochloride
  • Midazolam Hydrochloride
Trial OverviewThe trial is testing if IV ketamine works better than IV midazolam in treating MUD. Participants will be randomly assigned to receive one of the two drugs over a six-week period, as part of a 12-week study.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: KetamineExperimental Treatment1 Intervention
Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV ketamine will be administered 8 times over 6 weeks.
Group II: MidazolamActive Control1 Intervention
Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV midazolam will be administered 8 times over 6 weeks.

Ketamine Hydrochloride is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Ketalar for:
  • Anesthesia
  • Pain management
  • Depression
  • Suicidal ideation
🇪🇺
Approved in European Union as Ketamine Hydrochloride for:
  • Anesthesia
  • Pain management
  • Treatment-resistant depression
🇨🇦
Approved in Canada as Ketamine Hydrochloride for:
  • Anesthesia
  • Pain management
  • Depression

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Texas Southwestern Medical Center

Lead Sponsor

Trials
1,102
Recruited
1,077,000+

Findings from Research

In a study involving 140 out-patients undergoing maxillo-facial surgery, low-dose ketamine combined with midazolam was found to effectively reduce intraoperative anxiety and provide amnesia for the procedure, with patients reporting positive sensations compared to the control group.
The higher dosage of ketamine (0.5 mg/kg) not only maintained effective sedation during surgery but also improved postoperative vigilance, making it a suitable option for conscious sedation, while lower doses resulted in less favorable operating conditions.
[Analgesia-sedation for maxillo-facial surgery with midazolam-pentazocine and miazolam-ketamine. Clinical double-blind study of anxiety, analgesia, sedation and amnesia].Lipp, M., Daubländer, M., Sebastian, M., et al.[2019]
The combination of midazolam and ketamine is explored for its effectiveness in emergency medicine, particularly for sedation and pain management.
This combination may benefit specific patient populations, although the abstract does not provide detailed data on the number of subjects or specific outcomes.
Midazolam with ketamine: Who benefits?Kennedy, RM., McAllister, JD.[2017]
Ketamine hydrochloride has shown rapid and significant antidepressant effects in patients with treatment-resistant mood and anxiety disorders, although the studies supporting this have small sample sizes and limited long-term data.
While ketamine may offer benefits for some patients, there are important safety concerns and limitations in the existing research that must be considered when using it as an off-label treatment for psychiatric disorders.
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.Sanacora, G., Frye, MA., McDonald, W., et al.[2022]

References

[Analgesia-sedation for maxillo-facial surgery with midazolam-pentazocine and miazolam-ketamine. Clinical double-blind study of anxiety, analgesia, sedation and amnesia]. [2019]
Midazolam with ketamine: Who benefits? [2017]
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. [2022]
Intravenous ketamine is as effective as midazolam/fentanyl for procedural sedation and analgesia in the emergency department. [2022]
Comparative Evaluation of Ease of Dental Treatment and Clinical Efficiency of Midazolam vs Midazolam and Ketamine Combination for Sedation in Young Uncooperative Pediatric Patients: A Systematic Review. [2023]
Midazolam or ketamine for procedural sedation of children in the emergency department. [2018]
Use of intravenous ketamine-midazolam association for pain procedures in children with cancer. A prospective study. [2022]
The efficacy and safety of midazolam with fentanyl versus midazolam with ketamine for bedside invasive procedural sedation in pediatric oncology patients: A randomized, double-blinded, crossover trial. [2022]
Ketamine with and without midazolam for emergency department sedation in adults: a randomized controlled trial. [2013]
A 2 year experience of nurse led conscious sedation in paediatric burns. [2022]
[Drugs for intravenous induction of anesthesia: ketamine, midazolam and synopsis of current hypnotics]. [2019]
12.United Statespubmed.ncbi.nlm.nih.gov
Comparative evaluation of intravenous agents for rapid sequence induction--thiopental, ketamine, and midazolam. [2019]